Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Zhejiang Huahai Pharmaceutical Co., Ltd.
  6. Summary
    600521   CNE000001DL5

ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.

(600521)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
01/13/2022 01/14/2022 01/17/2022 01/18/2022 01/19/2022 Date
23.04 23.27 24.7 23.25 22.41 Last
20634540 15541150 40607370 29097570 20319320 Volume
-1.37% +1.00% +6.15% -5.87% -3.61% Change
Estimated financial data (e)
Sales 2021 8 115 M 1 279 M 1 279 M
Net income 2021 1 261 M 199 M 199 M
Net Debt 2021 - - -
P/E ratio 2021 25,8x
Yield 2021 0,49%
Sales 2022 9 959 M 1 570 M 1 570 M
Net income 2022 1 606 M 253 M 253 M
Net Debt 2022 - - -
P/E ratio 2022 20,4x
Yield 2022 1,14%
Capitalization 33 362 M 5 258 M 5 258 M
Capi. / Sales 2021 4,11x
Capi. / Sales 2022 3,35x
Nbr of Employees 6 655
Free-Float 54,5%
More Financials
Company
ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as... 
Sector
Pharmaceuticals
Calendar
04/26Earnings Release
More about the company
Ratings of Zhejiang Huahai Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
01/04Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announ..
CI
2021Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2021Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announ..
CI
2021Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2021Zhejiang Huahai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 millio..
CI
2021China stocks reverse course to close lower on profit-taking
RE
2021Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter..
CI
2021CITIC Securities Investment Limited, Jinshi Yikang Equity Investment Partnership (Limit..
CI
2021Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year End..
CI
2020Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd announced that it expects to receive ..
CI
2020Zhejiang Huahai Biological Technology Co., Ltd. announced that it expects to receive CN..
CI
2020Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2020Zhejiang Huahai Pharmaceutical Co., Ltd. Provides Financial Guidance for the Nine Month..
CI
2020Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2020Zhejiang Huahai Pharmaceutical Co., Ltd. Provides Earnings Guidance for the First Half ..
CI
More news
News in other languages on ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
2021Borsa Shanghai ritraccia e chiude in calo su prese profitto
2020Zhejiang Huahai Pharmaceutical Co., Ltd. fournit des prévisions financières pour les ne..
2020Zhejiang Huahai Pharmaceutical Co., Ltd. fournit des prévisions de bénéfices pour le pr..
2020Zhejiang Huahai Pharmaceutical Co., Ltd. annonce un dividende en espèces pour l'année 2..
2020Zhejiang Huahai Pharmaceutical Co., Ltd. fournit des prévisions de bénéfices pour le pr..
More news
Chart ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Zhejiang Huahai Pharmaceutical Co., Ltd. Technical Analysis Chart | 600521 | CNE000001DL5 | MarketScreener
Technical analysis trends ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 22,41 CNY
Average target price 15,50 CNY
Spread / Average Target -30,8%
EPS Revisions
Managers and Directors
Bao Hua Chen President & Director
Mei Zhang Chief Financial Officer
Hu Gen Wang Chairman-Supervisory Board
Su Zeng Independent Director
Yu Min Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.3.46%5 448
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992